Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, Inc. (ATHA) is a clinical-stage biopharmaceutical company pioneering novel therapeutics targeting neurodegenerative diseases through modulation of the HGF system. This page aggregates official press releases, clinical trial updates, and strategic developments related to their pipeline of small molecule candidates.
Investors and researchers will find timely updates on regulatory milestones, partnership announcements, and scientific presentations. Key content includes progress reports on lead candidate fosgonimeton (ATH-1017) for Alzheimer's disease, updates on oral therapies ATH-1020 and ATH-1105, and analyses of biomarker-driven trial outcomes.
All materials are sourced directly from the company's investor relations communications and verified industry publications. Bookmark this page for streamlined access to Athira Pharma's latest advancements in neuroprotection research and therapeutic development.
FAQ
What is the current stock price of Athira Pharma (ATHA)?
What is the market cap of Athira Pharma (ATHA)?
